Cancer poses a major challenge to development; it undermines socio-economic advances throughout the world. It is estimated that the number of patients with cancer would increase from 12.7 million in the year 2008 to 22.2 million by 2030. The European Journal of Clinical Oncology is conveniently placed in the scholarly communication milieu to help counter the menace of cancer by aiding the development of novel treatment strategies, by providing novel insights into the mechanisms underlying this complex disease.
Authors are requested to submit articles directly to online manuscript submission: https://www.scholarscentral.org/submissions/european-clinical-oncology.html
You may submit your paper as an attachment to this email:
2. Bibliographic Information
|Journal Name||European Journal of Clinical Oncology|
|Type of Access||Open Access|
|Type of Review||Peer review (Single blinded)|
|Publishing Type||Electronic version|
3. Aims & Scope
European Journal of Clinical Oncology strives to publish highest quality articles pertaining to clinical research, which are freely accessible to one and all. The scope of the journal encompasses topics including cancer biology, prostate cancer, colorectal cancer, cancer immunotherapy, chemotherapy, cancer radiology, therapeutic cancer, cancer pathology, surgical oncology, radiation oncology, diagnosis and treatment of cancer, bone marrow transplantation, etc.
In order to create highly impactful and original content, the European Journal of Clinical Oncology has gathered an expert Editorial Board, comprising of illustrious scientists who ensure that each manuscript is fairly, but stringently peer-reviewed. The decision on all submitted manuscripts will be taken independent of nationality, academic degree and relationship of the author with the journal. Papers will be published approximately 7 days after acceptance.
4. Types of Manuscripts
Research papers are based on novel researches. A research paper is a primary source of knowledge which includes the methods and results of a new study done by the authors. The kind of study may differ (it could have been an experiment, survey, interview, etc.), but in all cases, raw data have been achieved and analyzed by the authors, and conclusions drawn from the results of that analysis. Research articles follow a particular format.
European Journal of Clinical Oncology follows this content structure for research study:
All authors' information
|6||Experimental section (Materials and method)|
|7||Results and discussion|
|11||Conflict of interest|
4.2. Short communication
A brief research work considered as Short communication by Lexis publisher and European Journal of Clinical Oncology. Structure of Short communication defined similar to a research paper.
Important note: If a manuscript is submitted as an original research with brief and scant data then the editorial boards may consider the article as a Short communication.
Review articles are written based mostly on secondary data that is falling in line with the theme of the journal. They are brief, yet critical discussions on a specific aspect of the subject concerned. Reviews generally start with the statement of the problem with a brief abstract of 300 words and few key words. The main objective of Reviews is to offer systematic and substantial coverage of advanced topics, evaluations of development in identified subjects, and/or critical assessments of emerging knowledge. European Journal of Clinical Oncology follows this content structure for review:
|2||All authors’ information
(For corresponding author contact details must be provided)
|10||Conflict of interest|
4.4. Mini Review
The structure of a Mini Review is almost similar to that of a Review paper but generally it is concised to a word limit of 2200.
4.5. Case Report
A case report is a complete report of the symptoms, signs, diagnosis, treatment and follow-up of a specific patient. Case reports could cover a demographic outline of the patient, but generally explain an uncommon or novel occurrence. Some case reports also have a literature review of former reported cases. European Journal of Clinical Oncology follows this content structure for case report:
|2||All authors' information
(For corresponding author contact detail must be provided)
|11||Conflict of interest|
5. Article Processing Charges
Lexis Publisher is a self-financed and does not receive funding from any institution/government. Hence, the Journal operates solely through processing charges we receive from the authors and some academic/corporate sponsors.
Article Processing Charges
Special Issue article
The basic article processing fee or manuscript handling cost is as per the price mentioned above on the other hand it may vary based on the extensive editing, colored effects, complex equations, extra elongation of no. of pages of the article, etc.
Note: This publication charges are also applicable to invited authors.
6. Publication Ethics
For publication ethics related information please visit https://www.lexispublisher.com/more-pe.html
7. Medical Ethics
7.1. Informed consent
In general, informed consent assumes that authors are legally able to make their own decisions. For informed consent to take place, the information that’s given must be understood. The informed consent process is meant to give patients ongoing explanations that will help them make informed decisions about whether to start or stay in a clinical trial. The most important part of this process is their everyday interaction and discussions with the research team and other medical staff before, during, and after the trial. The consent form can be a great tool to help get this conversation started. This is all done so that patients can make the best decision for him/her, and to be sure that they are able to choose freely whether to enroll in or stay in the study. Much of this information may be on the consent form itself, which also regularly describes that they can withdraw from the study at any time without penalty. Before, during, and even after the clinical trial, patients will have the chance to ask questions and voice their concerns. Informed consent for clinical trials goes on for as long as the research lasts, and even afterward. Also Lexispublisher and European Journal of Clinical Oncology confirmed and followed WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects.
7.2. FDA (Food and Drug Administration) approval
The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the U.S. With many revisions, it is the most extensive law of its kind in the world. The law is planned to assure the user that foods are pure and healthy, safe to eat, and produced under healthy conditions; that drugs and devices are safe and effective for their proposed uses; that cosmetics are safe and made from suitable ingredients; and that all labeling and packaging is truthful, informative, and not deceptive. The authors should only use FDA approved products for medical studies on humans.
7.3. Animals in Medical Researches
Authors should take approval from relevant national or international bodies for experiments involving animal models. A copy of the approval letter must be submitted along with the manuscript or it should be clearly mentioned in the original manuscript.
8. Authors’ contribution
A statement of contribution make available validation for the order of authorship and it also assigns proper credit for academic contributions to the reported results. This is especially important where large research teams or multiple divisions within a company are involved in collaborative research.
The sample of Authors’ contribution is given below:
Author X contributed in all trials, coordinated the data-analysis and contributed to the writing of the manuscript.
Author Y is corresponding to the methods and experimental section.
Author Z designed the research strategy and prepared the study.
9. Authorship Changes
Corresponding author must declare the authorship details at the time of submission. Addition or removal of authors is usually not possible after the submission. We recommended the authors to read the COPE authorship guideline: http://publicationethics.org/files/u2/2003pdf12.pdf. Authors may directly contact the editorial office for queries related to authorship changes.
10. Conflict of Interest
A conflict of interest (COI) is a condition in which a person or institute is involved in several benefits (financial, emotional, or otherwise), one of which could possibly corrupt the motivation of the individual or organization. The occurrence of a conflict of interest is independent of the occurrence of impropriety. As per our guidelines, all authors should declare if any financial or other interests that may lead to a potential conflict either in the cover letter or at the end of the manuscript under the section “Conflict of Interest”. If there are no conflicts of interest, the authors should mention that in the manuscript.
11. Title page
Title page should be containing all author’s information (such as: first name, last name, email address and corresponding author) orderly. Also full research title should be mentioned in title page.
12. Manuscript highlights
Highlights are important points that convey the main results and provide readers with a rapid textual overview of the paper. These points describe the essence of the research (e.g. results or conclusions) and highlight what is distinctive about it. A sample of highlights is:
1.The goal of the work was to design a biosensor by using catalase and Tio2 nanoparticles as modifier
2. The good absorptivity and conductivity of Tio2 nanoparticles significantly enhanced the electrochemical detecting
3. Biosensor displayed many advantages such as excellent catalytic activity and low detection limit
Providing manuscript highlights are optional for Lexis publication and European Journal of Clinical Oncology.
13. Supplementary materials
When a paper is published, the Supplementary Materials are linked from the main paper html page and will be clearly marked in Lexis publication and European Journal of Clinical Oncology as Supplementary Materials. They can be cited using the same DOI that is applied to the paper. Supplementary Materials are optional and usually not refereed, but the referees or editor may recommend changes, including removing some unnecessary Supplementary Materials or moving items from the main text to the Supplementary Materials. Supplementary Materials can be modified in accordance with these suggestions and resubmitted along with a revised manuscript. Once the paper is accepted for publication, Supplementary Materials cannot be altered unless there is a strong reason found to eliminate an item.
14. Graphical Abstract
The graphical abstract is considered a part of the procedural content of the paper, and providing it, is optional during the paper submission process. The Graphical Abstract must be a brief, illustrative reflection of the content of your paper. We recommended: image Specifications Dimensions: 1000x400 File Types: JPG, JPEG, TIFF, PNG, GIF, Word, PS, EPS, PPT and BMP Recommended File Size: less than 600 KB. For image-only graphical abstracts, please label the file: graphical abstract.
15. Submission Criteria
15.1. Submission Method
Authors should submit the manuscripts as an e-mail attachment to [email protected]
15.2. Manuscript preparation
Manuscripts should be prepared as per the below format suggested by the publisher:
|Content Font||10 Times New Roman|
|Line spacing||2 cm|
|Title and font (Tables, Figures and Diagrams)||7 and Arial BOLD|
Clear, Editable formats
(The tables as images format is not acceptable.)
Clear, High resolution, Editable formats
(The figures should have high quality)
Clear, Editable formats
(The Equations as images format not acceptable and equations should be drawn with software and numbered.)
15.2.8. Subdivision - numbered sections
Manuscript should be divided into clearly defined and numbered sections. Subsections should be numbered also as below:
(then 1.1.1, 1.1.2, ...), 1.2, etc.
Any subsection may be given a short-term heading. Each heading should appear on its own separate line.
Note: The abstract should not be included in section numbering.
15.2.9. Manuscript important element properties
Title should be clear, meaningful and brief (no longer than 25 words). The abbreviations should not be used in the title.
An abstract for a manuscript is limited and should not exceed 350 words. Abstract should be summary of the main study. It should be written in complete sentences with factual information.
Keywords are limited and should be between 5-8 words, also should be separated with comma. For example: Biology, Medicine, Surgery, Enzyme.
All references should be prepared according to Vancouver style. A list of all the references cited in the text should be given at the end of the manuscript. They should be numbered consecutively in the order in which they are first mentioned in the text.
126.96.36.199. Reference Samples
Arefian Z, Pishbin F, Negahdary M, Ajdary M. Potential toxic effects of Zirconia Oxide nanoparticles on liver and kidney factors. Biomedical Research. 2015;26(1):89-97.
Park M, Yi JW, Kim EM, Yoon IJ, Lee EH, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) promotes adipogenesis and diet-induced obesity. Diabetes. 2015 Jan;64(1):117-27.
Note: Please list the first five authors and then add "et al." if there are additional authors.
Al-Kindi SG, Ali F, Farghaly A, Nathani M, Tafreshi R. Towards real-time detection of myocardial infarction by digital analysis of electrocardiograms. Biomedical Engineering (MECBME), 2011 1st Middle East Conference on; 2011: IEEE.
Gouvea C. Biosensors for health applications in biosensors for health, environment and biosecurity 2011.
Supriya A, Shruthi B, Kashyap B, Kumar G, Anand S. Pericoronal radiolucencies with significant pathology: Clinico-histopathologic evaluation, 2015 March 1, 2015. 148-52 pp.
16. Withdrawal Policy
From time to time, an author may wish to withdraw a manuscript after submitting it. Changing one’s mind is an author’s prerogative. And an author is free to withdraw an article at no charge – as long as it is withdrawn within 10 days of its initial submission. Author needs to pay complete processing fee if he/she wants to withdraw after 10 days.
17. License to use
The works published by LexisPublisher are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the work provided by the original work and source is appropriately cited.